美国血液透析患者SARS-CoV-2疫苗接受度全国调查
该研究在美国150家随机选择的透析机构中开展匿名在线调查,评估血液透析患者对COVID-19疫苗的犹豫程度。1515名患者(占合格者14%)回应,20%对所有疫苗犹豫,年轻、黑人、美洲原住民/太平洋岛民及女性患者犹豫 odds 更高,约半数犹豫者担忧副作用。结论认为需针对这些群体外展并解决副作用担忧。
要点
- 20%的血透患者对COVID-19疫苗犹豫,18-44岁及黑人患者中达29%。
- 年轻、黑人、美洲原住民/太平洋岛民及女性患者疫苗犹豫 odds 更高。
- 53%犹豫者担忧副作用,主要信息来源为电视新闻和透析工作人员。
核心结论
- 美国中心血液透析患者中相当比例对COVID-19疫苗犹豫,需针对年轻、女性及少数族裔患者外展并解决副作用担忧。
研究设计与样本
- 全国性疫苗接受度调查,与透析网络合作在150家随机选择的美国机构分发匿名英语和西班牙语在线问卷。
- 共1515名(占合格者14%)患者回应,采用逻辑回归分析疫苗犹豫者特征。
主要发现
- 20%的所有回应者、29%的18-44岁患者及29%的黑人回应者报告即使疫苗对普通人群安全仍犹豫接种。
- 疫苗犹豫 odds 较高人群:18-44岁 vs 45-64岁(OR 1.5,95%CI 1.0-2.3);黑人 vs 非西班牙裔白人(OR 1.9,95%CI 1.3-2.7);美洲原住民或太平洋岛民 vs 非西班牙裔白人(OR 2.0,95%CI 1.1-3.7);女性 vs 男性(OR 1.6,95%CI 1.2-2.0)。
- 53%的犹豫者表达对副作用的担忧。
- 回应者关于COVID-19疫苗的主要信息来源为电视新闻(68%)和透析工作人员(38%)。
临床怎么用
- 透析中心应针对年轻、女性及黑人、美洲原住民或太平洋岛民患者开展疫苗外展。
- 应解决患者对疫苗副作用的担忧,并利用透析工作人员作为信息传递渠道。
局限性
- 回应率仅14%(1515/合格者),可能存在无应答偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients on dialysis are at increased risk for COVID-19-related complications. However, a substantial fraction of patients on dialysis belong to groups more likely to be hesitant about vaccination. METHODS: With the goal of identifying strategies to increase COVID-19 vaccine uptake among patients on hemodialysis, we conducted a nationwide vaccine acceptability survey, partnering with a dialysis network to distribute an anonymized English and Spanish language online survey in 150 randomly selected facilities in the United States. We used logistic regression to evaluate characteristics of vaccine-hesitant persons. RESULTS: A total of 1515 (14% of eligible) patients responded; 20% of all responders, 29% of patients aged 18-44 years, and 29% of Black responders reported being hesitant to seek the COVID-19 vaccine, even if the vaccine was considered safe for the general population. Odds of vaccine hesitancy were higher among patients aged 18-44 years versus those 45-64 years (odds ratio [OR], 1.5; 95% confidence interval [95% CI], 1.0 to 2.3), Black patients versus non-Hispanic White patients (OR, 1.9; 95% CI, 1.3 to 2.7), Native Americans or Pacific Islanders versus non-Hispanic White patients (OR, 2.0; 95% CI, 1.1 to 3.7), and women versus men (OR, 1.6; 95% CI, 1.2 to 2.0). About half (53%) of patients who were vaccine hesitant expressed concerns about side effects. Responders' main information sources about COVID-19 vaccines were television news and dialysis staff (68% and 38%, respectively). CONCLUSIONS: A substantial proportion of patients receiving in-center hemodialysis in the United States are hesitant about seeking COVID-19 vaccination. Facilitating uptake requires outreach to younger patients, women, and Black, Native American, or Pacific Islander patients, and addressing concerns about side effects. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/JASN/2021_07_07_JASN2021010104.mp3.
引用
- Garcia P, Montez-Rath ME, Moore H, et al. SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. J Am Soc Nephrol. 2021. PMID: 33927004. doi:10.1681/ASN.2021010104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。